Ephrin type-A receptor 2 (EphA2) was identified in 1990, and various in vitro studies have described its role as a powerful oncoprotein that is highly overexpressed in cancer cells and is sufficient to confer malignant potential on non-transformed epithelial cells in the surrounding stroma or vasculature. This evidence concerns the gene EPHA2 and cancer.